<SEC-DOCUMENT>0001193125-19-159578.txt : 20190529
<SEC-HEADER>0001193125-19-159578.hdr.sgml : 20190529
<ACCEPTANCE-DATETIME>20190529160703
ACCESSION NUMBER:		0001193125-19-159578
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190529
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190529
DATE AS OF CHANGE:		20190529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		19862031

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d664406d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;29, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-21392</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2, Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT
STYLE="white-space:nowrap">240.14a-12)</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; <FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; <FONT
STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trading Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which<BR>registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1)&nbsp;Ordinary Share of Amarin Corporation plc</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AMRN</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">NASDAQ Stock Market LLC</TD></TR>
</TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2019, Amarin Corporation plc issued a press release titled, &#147;U.S. FDA Grants Priority Review for Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication&#148; (the &#147;Press Release&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d664406dex991.htm">Press Release, dated May&nbsp;29, 2019</A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;29, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Thero</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive
Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d664406dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g664406g82c76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>U.S. FDA GRANTS PRIORITY REVIEW FOR </B><B><I>VASCEPA</I></B><B><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (ICOSAPENT ETHYL) SUPPLEMENTAL NEW DRUG APPLICATION SEEKING CARDIOVASCULAR RISK REDUCTION INDICATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PDUFA date assigned is September&nbsp;28, 2019, four months sooner than expected </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Vascepa</I>, assuming approval, will be first drug indicated to reduce residual cardiovascular risk in
patients with statin-managed <FONT STYLE="white-space:nowrap">LDL-C</FONT> cholesterol, but persistent elevated triglycerides, as studied in the landmark
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> cardiovascular outcomes study </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cardiovascular disease is the No.&nbsp;1 cause of death for U.S. men and women </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amarin is accelerating plans for commercial expansion, based on Priority Review designation
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J.&nbsp;and&nbsp;DUBLIN, Ireland,&nbsp;May 29, 2019&nbsp;&#150;&nbsp;Amarin Corporation&nbsp;plc&nbsp;(NASDAQ:AMRN)
announced today that its supplemental new drug application (sNDA) for <I>Vascepa</I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules has been accepted for filing and granted Priority Review designation by the
U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this sNDA<I> </I>is September&nbsp;28, 2019. Because of the Priority Review designation, the timing of this PDUFA date is four
months earlier than the anticipated standard <FONT STYLE="white-space:nowrap">ten-month</FONT> review for applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming FDA approval,
<I>Vascepa</I> will be the first drug indicated to reduce residual cardiovascular risk in patients with statin-managed <FONT STYLE="white-space:nowrap">LDL-C</FONT> cholesterol, but persistent elevated triglycerides, an important indicator of
cardiovascular disease. This is a serious health challenge experienced by millions of people. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA grants Priority Review designation to applications
for drugs that, if approved, have the potential to offer significant improvements in the effectiveness and safety of the treatment of serious conditions when compared to standard applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We expect earlier approval of an expanded indication for <I>Vascepa</I> to lead to faster improvements in care for millions of patients with residual
cardiovascular risk after statin therapy,&#148; said John F. Thero, president and chief executive officer of Amarin. &#147;These patients will be the focus of our planned expanded <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> promotional efforts. We are very pleased that the FDA has accepted our application and granted it priority review. We believe the unprecedented <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
results position Amarin to lead a transformative change in clinical practice for preventative treatment of cardiovascular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disease, the leading cause of death for both men and women in the United States. Our plans to significantly expand promotion of <I>Vascepa</I> following label expansion are being accelerated to
reflect the upcoming PDUFA date.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>sNDA Based on Landmark <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sNDA for <I>Vascepa</I> is based on the landmark <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study, primary results of which
were published in <I>The New England Journal of Medicine </I>in November 2018<I>.</I><I><SUP STYLE="font-size:85%; vertical-align:top">1</SUP></I><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Additional results and analysis of total
recurrent events observed were subsequently published in the <I>Journal of American College of Cardiology </I>in March 2019.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP><I><SUP STYLE="font-size:85%; vertical-align:top">
</SUP></I><I>Vascepa</I> is currently indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG <U>&gt;</U>500 mg/dL) hypertriglyceridemia, an important but much smaller patient population than can be
addressed with an approval of this sNDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> <I>Vascepa </I>achieved the primary endpoint with a 25%
relative risk reduction compared to placebo (95% confidence interval [CI], <FONT STYLE="white-space:nowrap">0.68-0.83;</FONT> p&lt;0.001) in the first occurrence of a major adverse cardiovascular event (MACE) in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population. In <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> MACE consisted of a composite of cardiovascular death, nonfatal myocardial infarction (MI or heart attack), nonfatal stroke,
coronary revascularization (procedures such as stents and <FONT STYLE="white-space:nowrap">by-pass)</FONT> and unstable angina requiring hospitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As further evidence of the robustness of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results, <I>Vascepa</I> achieved the study&#146;s key secondary
endpoint with a 26% relative risk reduction (HR, 0.74; 95% CI, <FONT STYLE="white-space:nowrap">0.65-0.83;</FONT> p&lt;0.001) in <FONT STYLE="white-space:nowrap">3-point</FONT> MACE in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population consisting of a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke. <I>Vascepa </I>also achieved seven other secondary endpoints in the <FONT
STYLE="white-space:nowrap">pre-specified</FONT> hierarchical order below the key secondary endpoint, including a 20% relative risk reduction in cardiovascular death compared to placebo (HR, 0.80; 95% CI,
<FONT STYLE="white-space:nowrap">0.66-0.98;</FONT> p=0.03). <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> a global study of 8,179 statin-treated adults with elevated CV risk, was performed based on a special protocol assessment (SPA) agreement
with the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> adverse events occurring with <I>Vascepa </I>use at greater than 5% and greater than
placebo were: peripheral edema (6.5% <I>Vascepa</I> versus 5.0%), although there was no increase in the rate of heart failure in <I>Vascepa</I> patients; constipation (5.4% <I>Vascepa</I> versus 3.6%), although mineral oil, as used as placebo, is
known to lower constipation; and atrial fibrillation (5.3% V<I>ascepa</I> versus 3.9%), although there were reductions in rates of cardiac arrest, sudden death and myocardial infarctions observed in </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Vascepa</I> patients. More information on safety data associated with <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is provided below and in the published results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA Advisory Committee Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In its sNDA filing
acceptance communication to Amarin, the FDA did not indicate whether it plans to hold an advisory committee (AdCom) meeting to discuss this application. Amarin previously expressed that it believes an AdCom meeting organized by the FDA in
conjunction with its review of the expanded label for <I>Vascepa</I> is likely. It is not uncommon for clarification on this topic to be provided by the FDA later in its review process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc. is a rapidly
growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science.
<I>Vascepa</I> (icosapent ethyl) is Amarin&#146;s first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin&#146;s commercial partners are
pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin, visit<B><U>&nbsp;www.amarincorp.com</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>More About <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>, an
<FONT STYLE="white-space:nowrap">8,179-patient</FONT> cardiovascular outcomes study, was completed in 2018. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was the first multinational cardiovascular outcomes study that evaluated the effect of
prescription pure EPA therapy as an <FONT STYLE="white-space:nowrap">add-on</FONT> to statins in patients with high cardiovascular risk who, despite stable statin therapy, had elevated triglyceride levels (at least 135 mg/dL). A large portion of the
male and female patients enrolled in this outcomes study were diagnosed with type 2 diabetes.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information on the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study results can be found at<B>&nbsp;<U>www.amarincorp.com</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular
Disease</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide, cardiovascular disease (CVD) remains the No.&nbsp;1 killer of men and women. In the United States CVD leads to one in every three
deaths &#150; one death approximately every 38 seconds &#150; with annual treatment cost in excess of $500&nbsp;billion.<SUP STYLE="font-size:85%; vertical-align:top">3, 4</SUP><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple primary and secondary prevention trials have shown a significant reduction of 25% to 35% in the
risk of cardiovascular events with statin therapy, leaving significant persistent residual risk despite the achievement of target <FONT STYLE="white-space:nowrap">LDL-C</FONT> levels.<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the cardiovascular risk associated with <FONT STYLE="white-space:nowrap">LDL-C,</FONT> genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood), and <FONT STYLE="white-space:nowrap">TG-rich</FONT> lipoproteins, are at increased risk for cardiovascular disease.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;6, 7, 8,
9</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About </B><B><I>Vascepa</I></B><B>&nbsp;(icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vascepa</I> (icosapent ethyl) capsules are a single-molecule prescription product consisting of the <FONT STYLE="white-space:nowrap">omega-3</FONT> acid
commonly known as EPA in ethyl-ester form. <I>Vascepa</I> is not fish oil, but is derived from fish through a stringent and complex <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> manufacturing process designed to effectively eliminate
impurities and isolate and protect the single molecule active ingredient from degradation. <I>Vascepa</I>, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents
internationally based on the unique clinical profile of <I>Vascepa</I>, including the drug&#146;s ability to lower triglyceride levels in relevant patient populations without raising <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> levels.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indication and Usage Based on Current <FONT STYLE="white-space:nowrap">FDA-Approved</FONT> Label (not including
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results) </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Vascepa</I> (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult
patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The effect of <I>Vascepa</I> on the risk for pancreatitis and cardiovascular mortality and morbidity in patients
with severe hypertriglyceridemia has not been determined. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for <I>Vascepa</I> Based on Current <FONT
STYLE="white-space:nowrap">FDA-Approved</FONT> Label (not including <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results) (Includes Data from Two <FONT STYLE="white-space:nowrap">12-Week</FONT> Studies (n=622) (MARINE and ANCHOR) of Patients
with Triglycerides Values of 200 to 2000 mg/dL)</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Vascepa</I> is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to
<I>Vascepa</I> or any of its components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for
<I>Vascepa</I>, 1.0% for placebo). There was no reported adverse reaction &gt;3% and greater than placebo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving treatment with <I>Vascepa</I> and other drugs affecting coagulation (e.g., anti-platelet
agents) should be monitored periodically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients should be advised to swallow <I>Vascepa</I> capsules whole; not to break open, crush, dissolve, or chew
<I>Vascepa</I>. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT<B>&nbsp;<U>WWW.VASCEPA.COM</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for <I>Vascepa</I> based on <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> as previously reported in The New England
Journal of Medicine<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> publication of the primary results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study</U>:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Excluding the major adverse cardiovascular events (MACE) results described above, overall adverse event rates in <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> were similar across the statin plus <I>Vascepa </I>and the statin plus placebo treatment groups. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no significant differences between treatments in the overall rate of treatment emergent adverse events
or serious adverse events leading to withdrawal of study drug. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There was no serious adverse event (SAE) occurring at a frequency of &gt;2% which occurred at a numerically
higher rate in the statin plus <I>Vascepa</I> treatment group than in the statin plus placebo treatment group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events (AEs) occurring in 5% or greater of patients and more frequently with <I>Vascepa</I> than placebo
were:</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">peripheral edema (6.5% <I>Vascepa</I> patients versus 5.0% placebo patients), although there was no increase in
the rate of heart failure in Vascepa patients </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">constipation (5.4% <I>Vascepa</I> patients versus 3.6% placebo patients), although mineral oil, as used as
placebo, is known to lower constipation, and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">atrial fibrillation (5.3% <I>Vascepa</I> patients versus 3.9% placebo patients), although there were reductions
in rates of cardiac arrest, sudden death and myocardial infarctions observed in <I>Vascepa</I> patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were numerically more SAEs related to bleeding in the statin plus <I>Vascepa</I> treatment group although
overall rates were low with no fatal bleeding observed in either group and no </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
significant difference in adjudicated hemorrhagic stroke or serious central nervous system or gastrointestinal bleeding events between treatments. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In summary, <I>Vascepa</I> was well tolerated with a safety profile generally consistent with clinical experience
associated with <FONT STYLE="white-space:nowrap">omega-3</FONT> fatty acids and current <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling of such products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vascepa</I> has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult
patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. FDA has not reviewed and opined on a supplemental new drug application related to <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> FDA has not
reviewed the information herein or determined whether to approve <I>Vascepa</I> for use to reduce the risk of MACE. Nothing in this press release should be construed as promoting the use of <I>Vascepa</I> in any indication that has not been approved
by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Cautionary Information About These Data</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> data assessment and data release could yield additional useful information to inform greater
understanding of the trial outcome. For example, detailed data assessment by&nbsp;regulatory authorities, such as the FDA and Health Canada, will continue and take several months to complete and announce. The final evaluation by regulatory
authorities of the totality of efficacy and safety data from <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> may include some or all of the following, as well as other considerations: new information or analyses affecting the degree of treatment
benefit on studied endpoints; study conduct and data robustness, quality, integrity and consistency; additional safety data considerations and risk/benefit considerations; and consideration of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
results in the context of other clinical studies. Because regulatory reviews are typically fluid and not definitive interactions between sponsor and agency on individual elements of an application and related information, Amarin does not plan to
update investors on ongoing communications with regulatory authorities. Amarin plans to announce the final outcome of such regulatory reviews when appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recurrent event analyses for the total primary endpoint events and for the total key secondary endpoint in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
as published in the<I>&nbsp;Journal of the American College of Cardiology</I><I></I>&nbsp;were conducted using a series of statistical models. These analyses were tertiary or exploratory endpoints; most of the models used were prespecified and one
was <I>post</I> <I>hoc</I>. Each recurrent event statistical model has inherent strengths and weaknesses, with no single model considered definitive or outperforming the other models, and this is an evolving field of science. Nonetheless, results
from the total primary and total key secondary endpoint events analyses are consistent across the various recurrent event statistical models and are also consistent with the original primary and secondary endpoint results. Together, the
REDUCE-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IT recurrent event analyses and the original primary and key secondary endpoint analyses support the robustness of the clinical benefit of <I>Vascepa </I>therapy in reducing cardiovascular risk.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements, including expectations regarding FDA regulatory review, the applicability and reliability of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results, expected outcome and timing of review elements and market
dynamics for <I>Vascepa.</I> These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In addition, Amarin&#146;s ability to effectively commercialize <I>Vascepa</I> will depend in part on its
ability to continue to effectively finance its business, efforts of third parties, its ability to gain regulatory approvals, create market demand for <I>Vascepa</I> through education, marketing and sales activities, to achieve market acceptance of
<I>Vascepa</I>, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the
sale and promotion of <I>Vascepa</I> and to maintain patent protection for <I>Vascepa</I>. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties
associated generally with research and development, clinical trials and related regulatory reviews and approvals; the risk that sales may not meet expectations and related cost may increase beyond expectations; the risk that patents may not be
upheld in patent litigation and applications may not result in issued patents sufficient to protect the <I>Vascepa </I>franchise. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin
can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or
circumstances or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that Amarin communicates with its investors and the public using the company website (<B><U>www.amarincorp.com</U></B>), the
investor relations website (<B><U>investor.amarincorp.com</U></B>), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels,
including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin&#146;s investor relations website and may include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
social media channels. The contents of Amarin&#146;s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for
Hypertriglyceridemia.&nbsp;N Engl J Med 2019;380:11-22. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> Bhatt DL, Steg PG, Miller M, et al. Effects
of Icosapent Ethyl on Total Ischemic Events: From <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> <I>J Am Coll Cardiol</I> 2019. Epub ahead of print. https://doi.org/10.1016/j.jacc.2019.02.032. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;American Heart Association. 2018. Disease and Stroke Statistics-2018 Update. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections
through 2035. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia
therapy in hypertriglyceridemia management.&nbsp;J Am Coll Cardiol. <FONT STYLE="white-space:nowrap">2018;72(3):330-343.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP
STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease.&nbsp;Am J Cardiol. 2016;118:138-145. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased
cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk.&nbsp;J Am Heart Assoc.&nbsp;2018;7(15):e008740. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">8</SUP>&nbsp;Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease&#151;New
insights from epidemiology, genetics, and biology.&nbsp;Circ Res. 2016;118:547-563. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">9</SUP>&nbsp;Nordestgaard BG, Varbo A. Triglycerides and cardiovascular
disease.&nbsp;Lancet.&nbsp;2014;384:626&#150;635. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Investor Relations: </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>investor.relations@amarincorp.com</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646) <FONT
STYLE="white-space:nowrap">378-2992</FONT> <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>lstern@troutgroup.com</U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Media Inquiries: </U></I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gwen Fisher </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT STYLE="white-space:nowrap">325-0735</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>PR@amarincorp.com</B></U><B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g664406g82c76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g664406g82c76.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MR"@ Z?Y]*-O*P?A8!_G\*-OD&WR"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /%OVA/BWIOP.^$?C
M'XC:AY4DVC:;)#HEA*X4:IXCO_\ 0]#T[;U=)+^6)Y=H)6&&9_NH:ZL%A*F-
MQ%/#TOCE>VWV8N3W<5T[F->JJ-&<K7:M9;=4M[.UK_,_F&^*/PK\>_#L^#]<
M\<Z>EFWQ1\-0_$+2)8EV(]IK5S=S26MQ&(HUM=1A+PS26JKB*+4+7H' 'Z9A
M\5AZ\:RHU5)X=Q4DE):N^EVDM+:[]G9GR>(HRI23?VNGI9=]3JOV9?C1>_ 3
MXP^%/'\4DAT6&=M'\764;$?;_"FJM%!JJ! ?WD]KM@OX5Y_?Z?".A.<<PP$<
MPPGL_:^Q?1\O-:TXMZ<T;_#;RN3A:_U?$4FO[UUM]EI:V=MS^JG3-0LM5L;/
M4]-N8;S3]0M+:_L+RW=9(+JSNXEGMKB%U.'BDA='5AP0P(K\QDG%\K7*XGV,
M)*3DUMII^'EV+]26-)VXZ\>@ST]A1:Z:V$VH_H(& ]>/0$X_(4.ZV7XV'KU5
MA=WL1CU!7^8%2W-;0O\ ]O(+I=;"@_I1%M[KEMY@+T_SZ4V[!^@TMMQ_GI0F
M[.RNXVTN&WDD)O\ ;I[_ /UJI)V5_=?;?\03B]I;>3%#9[8Q[TI)QM97_ ;5
MK"@GTQCWS3:L+3H[@3C_ #Z4KI>0F[%?[5&)/(W1B<1B4P>8IE$9?RQ)Y8RW
ME[\KOV[=PQGO2=XVTNO4<7&3LG9KR_X8L Y'3'Z]*$]^R&U;Y"TQ"$XQQ_3I
M2U6RN-+Y6$W8[?TZ?A56_ +6\K#&GBCQOD1,YQO<)G&,XW=<9%/E?;85OP%6
M0/RF&4=&5LJ?H1Z5$>:[4H\O+:VM_P#AK#2^5A^?TH5];QY;;:W_ .&L2WRV
M#/Z?TJK6^0)W\K";L?A_GTI)I[/X2DGVM83=CM^O3'X4FXPM=\O;3MZ#Y?P#
M?CM^OI^%"=_*VQFI);^[;;J&[VZ>_P#]:F_=L-2ATEMY,-V.WZ^GX4KOHKV\
MRE9[/;R%!S^'^?2ES6^0-6\@+!?\^E-/\ 2_ -WMT_"A-I-R7*E\_P A\MO(
M-WX8HNK)WT?7T%8-V/PIZ(EOEL*#^E )W\K"T#$)VD#US^&*5[-+N)NS2MO^
M@9 _#]*?X6'L&<>V/PQBC;T0;?(,X_#\,4KI+LD"^X_*3]I"\G_:>_:O^&O[
M,6E,UUX!^&UQ%X[^+$L#LUO-<PPPW,FEW3QDJ/*T^XM-.4<E)_$LP(!M_E^E
MR]3R[ 5<?M.LH^RVTY)RIRZR3NI?:BO+74\/%\V+Q="C#W8T>>\M'?FA%K1V
M:Y7%K1NY]"_MQ? "+XT_ R_@T.RC/C#X>I-XJ\&16]OAKA;"V,>J^'((XBH6
M*_TM&CBA P;BULSC$>:\[)\8J.)BYODIU;J3WLXQFH[1;=V[65M[O8Z\RH*I
M#G^%PV6][N*WNK6W/YHD7Y1S^GL*_2FI.337*HVTWZ'QLZ-]>>S?2VUM.^MS
M]]/^"9OQ[;QO\-KWX0:_=>=XE^&422Z$TLNZ?4/ MW.RV2C=S(=)OY'L203M
M@FL%' S7PW$>!^K5HXF$N95[^Y:W+R1IQ^)MWYM]4K:+6Y]9E&)]M&5)KE=.
MUG>][N;VLK6M\[GZ?@Y]J^:3ND]CU]FUV,;Q%H.G>*-"UCPWJZ32:3KNF7VC
MZE%;W$]G-+8:C;26EU'%=VLD<UM(T$K@2Q.CJ3E2& (TIS=.2E'1QV_(B<.9
M6O9'X9_MY_LS^$_@/IOP[U_X5ZOXZM&\6>(+[PS>Z'?^+M;UFU>=;**YT^>R
MGO[U[F"5I%GC>-Y94?S58;/+(E^RR'%U,8Z\,1[RI\G)M&U_:-_"E>_*MWZ'
MSV8X;ZJJ<J4OBYKJW;E2W;[O8_-"[UGQ;I5U-!/K7B2PU+3+Y[>2*75M4BNK
M&]L9S'+'+&UT?+N(;N+!4\J\)!]OH?JM#$0BH^ZI7U][2S[-J][6\CRW6J4H
MQDWJ[WC9*UG;>S[W/ZB/V4_C-%\<_@CX/\;RRHVOI:#0?%\"\-;^*M&CBMM4
M9DP/+6ZS#?QKVBOXN3UK\WQ^%^J8B5*_,E9IVMO%-Z7>U^_8^LP=95*5U\U\
MVNR['T9G]*X6OE8ZT_+8^1_VT?C#>_"7X+:I%X;,K^/_ (A74/P^\!VEJQ%^
M^M>(%-K-?6D:$.9;.R>9XV0C%Q):#(WY'H93A'B<4U*/[JA9RE?JXR<=%)/=
M=+[:V6_%CJ[H4')1YGTC>WVHIZV:5K_UT_F@N-7\2V5S<V5UK.NPW-G/+;7$
M7]MZDWESP2-%*F1<\[9$89]J_2(PIMJ$'I'U]>I\O*M+F[KIMIIZ'ZV_L&?L
MM_#GXQ_"N?XD_$._\;ZSK2>-=1TNRM+?QGX@TK3+.UT)--G@/DZ=?127,TD\
M\C.TTK+M"JJ@;BWRV=YC7PF)^JT+0C!)R=D^:ZC):-/EY?)ZGJY=AJ>(I^UJ
MJ_\ *M5:SDGJFKWLMUH?M.B^4H4?P_A^E?(RE=WM8]Z,5322V_KU/$_VA/C'
M'\"?A3XD^)<GAO4_$ZZ$+2)--TV2*!5N-1N8["SN=3O9<_V?I"7<\"SW*13N
M@E7;&Q;(Z<!A5C<33HN7)\6MK[1;>EX]K;Z;]#GQ.(]A2<N7FY;:7MU2[/N?
M@-X-_;1^)=A^TEI?QY\8ZG/J,%S*-"\0>'[+?%I%IX O)PD^A:38EF$:6"XO
MX&8O)+=VWFS,[S.Q^ZQF14)8.E2HU/9;W?*WM.+6CJ+L]?.[/G</F$G5C4<=
M==+^36_+^A_2IHNLZ;K^E:=K>CW<%_I6K6-IJ>FWULX>WO-/OH$NK.ZA<#YH
MI;>1'4^C"OSF,94U[-KE<?\ A^E[?>?4TZJJ*Z7+;I^7Y&H0>,$KCTJOP-5I
MT/G?XO?LS?#CXR:M#XB\3W7C33=?L]#.A6>I^%?&GB#PXT-G'/=7<+-8Z=>)
M97-Q'/>3D23VTA*L$;<H '3A<94P4GR)24[73_NWV=M-W_DS&M0A62YE9QO9
MW?6U]+KL?S%:OXK\9QWU_82^-O&%S'97]]9H9_$VMOO6VNI85=E:^(W,L:DC
MD9SC&37Z?1H4U!M+EY;7U?=VZZ6/BY5W'F=KJ-K*^W?6Q^G7[#7[*WPK_:!^
M$FN^+OB2?&&H:_8>.-3T.VO+#QIXATQ5T^UTK1;J*-K>"],3R>==SDR,C,=W
M7@5\UGF85\%6I4L/:*CS7;2=](-;IVMS6LO5OHO5P.#I8R$IU/LVLM=-9)[-
M?RF]^T7^PUXH^"_A'6?B?^SW\4/B/!;^%;675];\*W?B34$U.'2+,>9>:AH6
MKZ9);&X:T@\R:2SNH79XH79)BZ^7+A@<W^M5(X?%0OS?#+FY4FDY-6C%-\UD
ME=Z=[NSWQ&!^ITW/#U.3^9<M[V:2UE)VM=[+4\(^ ?\ P4:^+OP]U/3]+^*%
MW<?$[P3+(B7TU\(QXRTJ D[[K3-755_M9H@0YM=1\PR+&RK<1$EJZ\7D%"O"
M%2A-85QOS147/FNTH[U$ERV;T6M]=CDP68U*<:CJQY[\ME=*UG*^JB]]#]]_
M"?BC0_'/AG0_%_AG4(M3\/\ B'3+/5](OXE8+<V5]"D\+E) &BE"L%>)PKQN
MKQN Z$#XNI3G3GR-\KCNOEIJ?2T9QG"Z6DNFUK-K]/D?D9^WC^S!\.?A)\*K
MKXH^ ;WQKHWB&7QKI=I>V\OC/7]2TF\@\17-Z]Y_H>H7LIM9$F57B:"2,+RN
MTC;L^DR/'5:V*6%FERU$[/9Q<%*6R2NG9JSVTUT=_&S'"PH4G6@[.+U6NNL4
MM;NUK]M3\>CK^O\ _0>UL8_ZBVH\?^3-?8^Q5.$];O2VEK:^IX2K>^X\ND;=
M>Z]-+']#WA3_ ()Y? FW\,Z5;ZW?_$?Q#J\MC:2WNNS^/_$NF3SW,D"22O!8
MZ5J$-K:0EF(6(1R%55078@LWYY5S?%5)W34%#96B^B3NW'R[+YGTW]F4I17-
M-WCY-?AS>1^9/[9/[/3_  8^,'@KP%\(];^(&MQ^//#HU+3- OM?U'5=4BU:
M+4+VQ:PT^Y6>-[Q)X[021QR+O5]R!W\Q0OU&2XYXRCB)XII.@X)6T7ON5_A2
MM:RWOY6/+QF#A1Y%!VO?H^G+W;/BG2/&GC7PWJ]CK&D^*O$NEZUHM_%>6%W'
MJ^HI=Z?J%E*=K-%<3,!)'*N&BD4J<,DBD%EKVW0H5*+YZ>D]M9='9Z7UOMJ>
M9"K5HR]WW+;K1^FMG:U^A_19^QO^UWHO[17ADZ+KC6FC_%?PY9Q_\)#HJ,+>
MVURTC+1KXGT")C@VLK[/M-JI9[263!S"T+O^>9OETL%*$H/GISOY.#7+H]7I
MJK/Y/HW]-EF,^LJJIKD=/EMUO?F[);6/MF>".YAEMY-WE31O%($9HV,<BE6"
MNA#(Q4D;E((Z@@X(\B*2:DOL[/\ !GJ65K-71^3/[7?[%OA+P3\'O%7Q)^%_
MBWXB>']7\$6AUV^TK4/'7B37=+UK2XYXDOX@NJZA--9ZC##(TT$L4NQO):)X
MR91)']/D^:XCZQ##U??A4O\ RQMRQG+I"[N[=5:QXN/P25-UHSM[/[-N[C'>
M^EM]O(T?V&_V4O"NJ?#[X>?'?QSKWC#Q%XRU*^3Q9X<LV\5ZW!H6A6^F:I-%
MHZS:?#=)_:EV[60N9UNWFA/G)'Y6%8R9YSFE>>(J8.G:G3ARW^&5^:,)]8IK
M6ZW?Z$X#"Q5#VKE?VFT;6Y>24H[WUOZ*WF4/BSXOO]1C_P"%@^)+)?%EQKFO
M_'.QTOPSJUOXLU'P_P""-*^$?B"Q\*:!IEO8>'_%^AV_A>;4;PR7>M>+;W[5
M)9-J$382UMP@BC35/VE*,E^[4;RM9R<N;5Q;:CRK1;WLV^B6]1<EK:<U_32W
MW;GW)\"M0UBPU+XE_#G4M3U#7;'X>ZYX=C\/ZEJFH/K.J6>D>*O"NF^)5\+:
MEKDF9=;GT2ZN[FWAOKAFN);&;3S.S2 N_E8AJ:IU.7EE/FYETNFE?Y]?\[WZ
M<(W^\5[\O+;\3Z&S]?R-<QV",.G;;VZ=?Y5+6L7MRC3LFN_Z'Y?>+OB3X-T_
MQ1XFT^[_ &G/VN-+N[37=7M9].TCX92W.E:?+!?7$3V>E747PKF6ZTZ!E,<$
MRSRB2.-'$C[M[?24</5=*FXY?@YIQ5G*HN;_ +>7M59]U8\>=6$9R3Q5>+3V
M4-%Z>Z<5+\3? (_=R_M=_MEQD8.T?#:^A<8Z<K\+E;&/?%:+#5_^A;@?_!B_
M^6F?MZ:_YB\2O^W'_P#(G&^,OC#\/]"\.ZSJEG^U_P#M@3ZM9:;=2Z3INH^%
MY]$M-1U189#IVGS7VH^ ;6VM%N+L1QF:650JL6R=H%;4<!B*LXT_[+PC4O\
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ME9F^545;?G_#D/HO]LGX)_\ "\O@5XI\.6-NLWBK0D'BSP:VU3*=>T6.23[
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
